PORT HUENEME, CA, (September 23, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today, further to its news releases of August 22, 2013 and September 10, 2013, the closing of its private placement raising total gross proceeds of US$12,000,000 (the “Private Placement”). The proceeds of the Private Placement will be used for product research, aquaculture and KLH production development, capital expenditures and working capital.

“We are very gratified by the successful and strong closing of this offering. With a sound balance sheet, validation from industry investment, and continued support from Stellar’s major shareholders, we can execute our expansion plans with confidence,” said Frank Oakes, Stellar President and CEO. “Our team is eager to capitalize on the broadened recognition for Stellar’s immunotherapy research and KLH leadership, and turn each strategic initiative into long-term shareholder value.”

Dr. Tessie Che is currently Chair of the Board of Directors of Amaran Biotechnology, Inc., a private biotech company based in Taiwan. Stellar’s recent US$12 Million Private Placement included a $5 Million investment by Amaran Biotechnology.

“Dr. Che brings to Stellar extensive experience pertinent to our key corporate goals at this high-growth stage,” said Frank Oakes, Stellar President and CEO. “She co-founded and successfully led a biopharmaceutical firm from development to commercialization of a new drug product to treat Clostridium difficile. In addition, Dr. Che has extensive scientific and operations acumen, as well as strategic ability transforming research programs and pipelines into high-value business assets.”

“It is my pleasure to join Stellar’s Board of Directors,” said Tessie Mary Che, Ph.D. “Stellar’s proprietary strength in KLH protein manufacturing and its vision to target the active immunotherapy market makes this an impressive company with very high commercial potential.”

Dr. Che co-founded Optimer Pharmaceuticals, Inc. (OPTR:NASDAQ) in 1998 and served over ten years as Optimer’s Chief Operating Officer and Senior Vice President of Corporate Affairs. During the process development years of Optimer’s flagship drug, DIFICID®, Dr. Che built and led the company’s Chemistry, Manufacturing and Quality Control (CMC) teams through the successful and cost-effective registration and commercialization of DIFICID® in the United States, Canada and Europe in 2011.

Prior to Optimer, Dr. Che’s industrial experience included 20 years in research, management and operations at large companies including Exxon Mobil Corporation, Aventis Pharmaceuticals, Inc., and EniChem S.p.A. She also served as Vice President, Operations of M and D Precision Science Group, Inc. in 1988 and co-founded Cinogen Pharmaceuticals, Inc. (China) serving as Vice President from 1994 to 1996. Cinogen later became a wholly-owned subsidiary of Pharmanex, Inc., where Dr. Che served as Sr. Director of Quality Assurance and Sourcing.

Dr. Che holds bachelors’ degrees in chemistry from Illinois State University and Fu-Jen Catholic University (Taiwan), a Ph.D. in physical-inorganic chemistry from Brandeis University, and did post-doctoral work at Columbia University. She has authored numerous scientific publications and holds over twenty U.S. patents in material synthesis and applications.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

Please find below links to Stellar Biotechnologies’ Corporate Profile and Investor Presentation. These materials have been updated to reflect the recent successful Private Placement financing and are now available on Stellar’s corporate website.

We are pleased to report that a second scientific abstract representing the Company’s KLH active immunotherapy program on Clostridium difficile infection (“C. diff”) has been accepted for presentation at the 7th Vaccine & ISV Congress to be held October 27-29, 2013 in Barcelona, Spain.

The poster will be titled “Immunization with Clostridium difficile PSII polysaccharide antigens adjuvanted with KLH induced broad-based enhancement of adaptive immune responses and protection in mice.”

This will be the second of two presentations this month related to Stellar’s C. diff immunotherapy program:

These presentations are indicative of the development being generated under Stellar’s newly acquired, exclusive license to active immunotherapy technology for the treatment and diagnosis of Clostridium difficile. Stellar’s scientists are working closely with researchers at the University of Guelph (Ontario, Canada) to advance this program.

About Clostridium difficile

Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported in 2009. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Port Hueneme-based Stellar Biotechnologies has closed a $12 million round of financing and acquired a license for what could one day be its first drug.

Stellar gained notoriety in the research world by snatching up a facility inside the Port of Hueneme gates during a round of base closings in the late 1990s. It used that facility to sustainably cultivate giant keyhole limpets. The mollusks produce what is known as keyhole limpet hemocyanin, or KLH, a carrier protein for vaccines that previously had to be harvested from the wild.

Frank Oakes, Stellar’s CEO, said the company has been focused on moving up the value chain. In the past, it provided raw KLH material that other companies would then purify and sell to researchers for integration into therapies. Stellar has developed the ability purify its proteins in house. And in July, it acquired a license to patents covering a potential treatment for infections of Clostridium difficile, or C. diff, a common infection in hospitals. Read the full story…..

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

PORT HUENEME, CA, (October 21, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH), announced today presentation of positive results from a preclinical study of the Company’s KLH-conjugate active immunotherapy vaccine demonstrating protection against Clostridium difficile (“C. diff”) infection in mice. The study results are being presented this week at the 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClostPath 8) in Queensland, Australia, October 22-26, 2013.

Clostridium difficile is a bacteria found in the intestines that can cause severe and life-threatening intestinal conditions. C. diff infections are at an all-time high and related hospitalizations have tripled in the last decade.

The oral presentation titled “An Anti-C. difficile PSII Polysaccharide-KLH Conjugate Vaccine is Efficacious in Mice” is the result of preclinical research conducted together by scientists from Stellar and the University of Guelph (Ontario, Canada) (“Guelph”). The work relates to Stellar’s newly acquired active immunotherapy technology targeting the treatment and diagnosis of C. diff.

Stellar’s active immunotherapy technology for C. diff targets cell-surface antigens expressed across many strains of C. diff bacteria. Stellar’s approach combines selected polysaccharides of C. diff with Stellar KLH as carrier and adjuvant. The presentation at ClostPath 8 describes the design of a PSII-KLH immunotherapy vaccine and its evaluation in a murine model of C. diff infection.

In the study, the data demonstrated that vaccination with a PSII-KLH conjugate vaccine was effective in conferring protective immunity against C. diff infection, by improving survival in vaccinated mice compared to unvaccinated controls. The study results suggest that Stellar’s PSII-KLH active immunotherapy technology shows promise as an effective approach to treating C. diff. Additional preclinical research is underway.

ClostPath 8 is the preeminent scientific conference in the field of clostridial pathogenesis. The meeting covers the latest discoveries presented by leading international researchers.

About Clostridium difficile

Clostridium difficile is a major and growing cause of mortality and morbidity in hospitalized patients. C. diff is a type of bacteria normally present in the intestine, but which can overgrow as a result of antibiotic use. It causes severe diarrhea and life-threatening intestinal conditions such as colitis. Incidence of C. diff is at a record high in the U.S. with more than 330,000 cases reported annually. Deaths related to C. diff increased 400% in recent years. The cost of C. diff related treatment in the U.S. and Europe is estimated at more than $7 billion annually.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

As you may know, Stellar Biotechnologies (TSX-V: KLH) (OTCQB: SBOTF) (“Stellar”) is traded on the Canadian TSX Venture Exchange and the U.S. OTC QB Marketplace Exchange.

Effective yesterday, Stellar was one of six TSX Venture Exchange companies added to the S&P/TSX Venture Select Index. The S&P/TSX Venture Select Index measures the combined performance of constituents in the S&P/TSX Venture Composite Index that meet specific market capitalization and liquidity criteria.

The S&P/TSX Venture Select Index is calculated and managed by S&P Indices. The Toronto Stock Exchange (TSX) is the owner and distributor of all S&P/TSX equity index data. Index constituents must meet minimum size and liquidity requirements to ensure investability and tradability.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Neovacs has three Kinoid drugs in clinical trials using Stellar KLH: One IFN-K drug for lupus as well as two TNF-K drugs for Crohn’s disease and rheumatoid arthritis. Neovacs’ Kinoid drugs are immunotherapies that rely on Stellar KLH to stimulate an antibody response to the targeted cytokine. Excessive cytokine production is implicated in multiple diseases including rheumatoid arthritis, lupus, Crohn’s and cancer.

In Neovacs’ press release, their new CEO Miguel Sieler said, “This innovative approach demonstrates Neovacs' ambition to make Kinoids the next generation treatment for autoimmune and inflammatory diseases, and more specifically Rheumatoid Arthritis, Crohn's Disease and lupus. My goal is to bring these products to world markets and build value-creating partnerships for investors.”

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

“I am delighted to have Ms. Niffenegger and Dr. Brisson take on broader executive roles within Stellar and leverage their proven successes managing critical areas of our business,” said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. “I look forward to leveraging their leadership to advance the multiple growth opportunities the Company has in sight.”

Ms. Niffenegger began working with Stellar in 1999, as outside CPA. She became Controller for Stellar Biotechnologies in 2012 and assumed the role of Corporate Secretary earlier this year. Ms. Niffenegger is a Certified Public Accountant with more than 30 years of experience in accounting and finance in a range of industries. Ms. Niffenegger was previously technical partner in the audit division of Glenn Burdette CPAs, obtained CFO experience at Martin Aviation and began her career at Peat, Marwick, Mitchell & Co. (now KPMG LLP). She held leadership roles for audits of manufacturing, aquaculture, pharmaceutical, and governmental grant clients, and developed specific expertise in cost accounting systems and internal controls. Ms. Niffenegger holds a B.S. degree in Business Administration from California State University, Long Beach.

Mr. Oakes said “Kathi is a seasoned finance executive who has been a key contributor to Stellar Biotechnologies’ growth for over fourteen years. We are very fortunate to have a CFO with both her extensive experience and in-depth knowledge of our business, overseeing the financial resources and assets that are vital to our long-term plan.”

Dr. Brisson joined Stellar in 2010 as Director of Quality and Regulatory Affairs, and was promoted to Chief Pharmaceutical Officer in 2012. She has more than 20 years of experience in the biotechnology, pharmaceutical and medical device industries with strong expertise and broad scientific and operational understanding in quality assurance, quality control, regulatory affairs, manufacturing, and product development areas. Dr. Brisson has held past positions in both startup and established companies such as MacuSight and Teva Parenteral Products. Dr. Brisson holds a B.S. degree in Chemistry from North Carolina State University and a Ph.D. in Organic Chemistry from the University of North Carolina.

Commenting on Dr. Brisson’s elevated role as Chief Operations Officer, Mr. Oakes said, “Catherine brings together pharmaceutical industry experience with a deep understanding of KLH production, quality control and regulatory compliance. She has a progressive vision for ensuring unmatched operations that will support Stellar’s immunotherapy customers on multiple fronts, while providing critical input on Stellar’s strategic development programs.”

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

We would like to remind you that you are invited to join in on Stellar Biotechnologies' corporate update conference call tomorrow (December 11) at 11:00 AM ET.

The Company will review the significant milestones achieved in 2013 including its acquisition of exclusive rights to an innovative KLH-based immunotherapy technology to treat Clostridium difficile infection (“C. diff”), as well as recent manufacturing and R&D progress. In addition, Stellar’s management will discuss the Company’s plans for expansion involving potential catalysts in R&D, manufacturing and business development.

For the live and archived webcast, please visit the investor presentation section on Stellar Biotechnologies’ website at: www.stellarbiotech.com

A replay of the call will be available through December 25, 2013. To access the replay, please call 1-877-870-5176 if calling from North America and 1-858-384-5517 if calling from outside the U.S. and Canada. The replay passcode is 4653815, for additional information please visit the investor section of the company website at www.stellarbiotech.com.

Amaran designs, develops, and manufactures active immunotherapies such as OBI-822, the lead immunotherapy product of OBI Pharma, Inc. The primary purpose of the alliance is to develop and evaluate methods for the manufacture of the OBI-822 active immunotherapy using Stellar’s GMP grade KLH.

OBI-822 is a new generation of active immunotherapy combining Globo-H, a carbohydrate antigen frequently expressed by cancer cells, together with KLH as the immune-stimulating carrier molecule. An active immunotherapy uses a patient’s own immune system to recognize and mount an attack against the targeted tumor cells. OBI-822 is currently being evaluated for the treatment of metastatic breast cancer in International Phase 2/3 clinical trials* in the United States, Taiwan, South Korea, India and Hong Kong. It is also being evaluated for the treatment of ovarian cancer in an investigator-initiated Phase 1/2 clinical trial in Taiwan.

* OBI-822 is in Phase III in Taiwan and Phase II in the U.S., South Korea, India and Hong Kong

“This is an important, multinational clinical project and Stellar is very pleased to collaborate with Amaran on the manufacture of Immunotherapies such as OBI-822” said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. “This is an excellent example of Stellar KLH™ technology serving as a platform for partnerships with long-term product development and commercial potential.”

Catherine Brisson, Ph.D., Chief Operating Officer for Stellar said, “KLH is a key active ingredient in immunotherapy drugs. Our goal is to ensure that partners such as Amaran have future supply of the highest-quality KLH to meet the specifications of each particular immunotherapy drug.”

“We are pleased to have Stellar Biotechnologies’ key technical advances in KLH applied to this important cancer active immunotherapy program,” said Tessie Che, General Manager and Chair of Amaran’s Board of Directors. “We look forward to working closely with the Stellar team on this development project.”

Under the terms of the agreement, Stellar will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in OBI-822 immunotherapy. Stellar will also be responsible for method development, product formulation, and process qualification for certain KLH reference standards. Amaran will be responsible for development objectives and product specifications.

The agreement provides for Amaran to pay to Stellar fees for certain expenses and costs associated with the development program. Subject to certain conditions and timing, the collaboration also provides for the companies to negotiate a commercial supply agreement for Stellar KLH™ in the future.

About Amaran Biotechnology, Inc.

Amaran Biotechnology, Inc. is a privately-held Taiwan biopharmaceuticals manufacturer. Amaran is engaged in the business of designing, developing and manufacturing pharmaceuticals and biotechnology products, including KLH-conjugated active immunotherapies such as OBI-822, the lead immunotherapy product of OBI Pharma, Inc. OBI-822 is a Globo-H-KLH conjugate active immunotherapy under Phase 2/3 clinical evaluation for the treatment of metastatic breast cancer.

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.